// App-Quantinova.ai

817 : Protective-2 (BPI-2358-106): A Confirmatory Trial to Demonstrate Superiority of the Plinabulin+Pegfilgrastim (Plin/Peg) Combination Versus Standard of Care Pegfilgrastim for the Prevention of Chemotherapy-Induced Neutropenia (CIN) in Breast Cancer (BC) Patients (pts)

Researchers

Presenter

  • Douglas W. Blayney

Principal Investigators

  • Ramon Mohanlal

  • Lan Huang

Medical Centers

  • Stanford Univ, Palo Alto, CA

  • BeyondSpring Pharmaceuticals, New York, NY

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Chemotherapy-induced neutropenia

  • Thrombocytopenia

  • Breast cancer

  • Neutropenia

  • Solid malignancies

Biomarkers

  • Chromosomal instability

Drug/Treatment

  • Cyclophosphamide

  • Cyclophosphamide Injection

  • Pegfilgrastim

  • Doxorubicin

  • Plinabulin

  • Docetaxel

  • Filgrastim

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Double Blind/Blinded

  • Superiority

  • Multicenteric

Phase

  • II

Study Id's

  • NCT0329457

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved